Bridgeway Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Bridgeway Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$344K	Buy	64,500 +11,000	+21%	+$47.9K	0.01%	945
2026 Q1	$183K	Hold	53,500	–	–	﹤0.01%	1051
2025 Q4	$155K	Hold	53,500	–	–	﹤0.01%	1060
2025 Q3	$77K	Sell	53,500 -35,000	-40%	-$35.1K	﹤0.01%	1133
2025 Q2	$71.6K	Hold	88,500	–	–	﹤0.01%	1108
2025 Q1	$68K	Sell	88,500 -22,500	-20%	-$21K	﹤0.01%	1097
2024 Q4	$142K	Sell	111,000 -65,100	-37%	-$86.4K	﹤0.01%	1060
2024 Q3	$365K	Buy	176,100 +52,500	+42%	+$243K	0.01%	932
2024 Q2	$471K	Hold	123,600	–	–	0.01%	871
2024 Q1	$586K	Sell	123,600 -25,149	-17%	-$97.8K	0.01%	880
2023 Q4	$635K	Buy	148,749 +111,800	+303%	+$340K	0.01%	881
2023 Q3	$114K	Hold	36,949	–	–	﹤0.01%	1200
2023 Q2	$166K	Hold	36,949	–	–	﹤0.01%	1176
2023 Q1	$211K	Hold	36,949	–	–	0.01%	1097
2022 Q4	$223K	Hold	36,949	–	–	0.01%	1065
2022 Q3	$244K	Sell	36,949 -10,000	-21%	-$67.4K	0.01%	1094
2022 Q2	$245K	Buy	+46,949	New	+$239K	0.01%	1048

Other funds holding PRLD

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Bridgeway Capital Management's PRLD Position: Q2 2026 in Review

Bridgeway Capital Management increased its Prelude Therapeutics (PRLD) stake by 21% in Q2 2026, buying an estimated $47.9K and bringing the position to 64,500 shares worth $344K. The position accounts for 0.01% of the portfolio, ranked #945.

Bridgeway Capital Management first reported a position in PRLD in Q2 2022 and has held it in 17 quarters since. The position peaked at $635K in Q4 2023. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

Bridgeway Capital Management held 64,500 shares of Prelude Therapeutics worth $344K as of Q2 2026.
Bridgeway Capital Management bought 11,000 Prelude Therapeutics shares in Q2 2026, an estimated $47.9K.
Prelude Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #945 holding.
Bridgeway Capital Management first reported a position in Prelude Therapeutics in Q2 2022 and has held it in 17 quarters since.
Bridgeway Capital Management's Prelude Therapeutics position peaked at $635K in Q4 2023.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.